The estimated Net Worth of Peter Altman is at least 911 千$ dollars as of 28 June 2019. Peter Altman owns over 600 units of BioCardia stock worth over 233,449$ and over the last 7 years he sold BCDA stock worth over 0$. In addition, he makes 677,501$ as President、 Chief Executive Officer、 Director at BioCardia.
Peter has made over 26 trades of the BioCardia stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 600 units of BCDA stock worth 5,226$ on 28 June 2019.
The largest trade he's ever made was buying 11,000 units of BioCardia stock on 30 April 2019 worth over 11,880$. On average, Peter trades about 1,905 units every 17 days since 2018. As of 28 June 2019 he still owns at least 85,827 units of BioCardia stock.
You can see the complete history of Peter Altman stock trades at the bottom of the page.
Dr. Peter Altman Ph.D. serves as President, Chief Executive Officer, Director of the Company. He has served as our President and Chief Executive Officer since 2002, where he has global responsibility for the development, manufacture and marketing of our therapeutic candidates and products. He was founding Chief Executive Officer from 1999 to 2003 and board member of CareDx from 1999 to 2014, a developer of a diagnostics to be used in chronic inflammatory diseases, including cardiac transplantation. He was also founding Chief Executive Officer for Lumen Therapeutics from 2004 to 2005, an early-stage pharmaceutical company. He has 33 years of experience in life science research and product development, is named inventor in more than 50 U.S. patents, and has authored 40 scientific publications. Dr. Altman currently serves as a director on the board of directors of Oncocyclist Biotech, since 2018. He received his Ph.D. in Bioengineering/Pharmaceutical Chemistry from the University of California, San Francisco and University of California, Berkeley, his Management of Technology certificate from the Walter A. Haas School of Business at the University of California, Berkeley, and both his Master of Science and Bachelor of Science in Mechanical Engineering from the Columbia University School of Engineering and Applied Sciences. Dr. Altman has been elected Fellow of the American Heart Association.
As the President、 Chief Executive Officer、 Director of BioCardia, the total compensation of Peter Altman at BioCardia is 677,501$. There are no executives at BioCardia getting paid more.
Peter Altman is 53, he's been the President、 Chief Executive Officer、 Director of BioCardia since 2016. There are 12 older and 1 younger executives at BioCardia. The oldest executive at BioCardia Inc. is Simon Stertzer, 83, who is the Independent Chairman of the Board.
Peter's mailing address filed with the SEC is C/O BIOCARDIA, INC., 320 SOQUEL WAY, SUNNYVALE, CA, 94085.
Over the last 8 years, insiders at BioCardia have traded over 2,555,815$ worth of BioCardia stock and bought 6,474,371 units worth 6,325,055$ . The most active insiders traders include Phillip Md Et Al Frost Gamm...、Simon H Stertzer、Richard M Krasno. On average, BioCardia executives and independent directors trade stock every 48 days with the average trade being worth of 1,321,186$. The most recent stock trade was executed by Phillip Md Et Al Frost Gamm... on 19 January 2024, trading 129,802 units of BCDA stock currently worth 55,815$.
we are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. biocardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its cardiamp™ and cardiallo™ therapies. clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. these programs are enabled by the company's helix™ transendocardial delivery systems and morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.
BioCardia executives and other stock owners filed with the SEC include: